JulieKanterMD

Faculty Attending and Clinical Director of the Rape Treatment Center

Dr. Kanter is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
6200 SW 73rd St
South Miami, FL 33143
Phone+1 786-662-0455

Fax+1 786-662-5251

University of New Mexico School of MedicineResidency, Emergency Medicine, 2006 - 2009
Case Western Reserve University School of MedicineClass of 2006

Abstracts/Posters

Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel
Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy
Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Impact of Different Pediatric Estimated GFR Equations on Reporting of Renal Outcoms
Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Barriers and Facilitators to Transcranial Doppler Screening for Stroke Prevention in Children with Sickle Cell Anemia: Results from the Displace Consortium
Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study
Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Advancing Science in Sickle Cell Disease: Implications for the Future of Care
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Pediatric Clinical Non-Malignant Hematology
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Insurance Requirements for Prior Authorization May Prompt ‘Devastating’ DelaysMarch 10th, 2023
New Gene Therapies Are a near-Cure for Louisiana's Sickle Cell Patients. But at $1-2M, Who Will Pay for It?March 5th, 2023
Specialized Centers Can Help Realign the U.S.’s Moral Compass for Sickle Cell DiseaseDecember 21st, 2022
Join now to see all